Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease (Q34383685)

1 August 2017

title

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease (English)

1 reference

1 August 2017

0 references

John J McMurray

0 references

Giuseppe Remuzzi

0 references

Janet Wittes

1 reference

1 August 2017

Hans-Henrik Parving

1 reference

1 August 2017

Robert D Toto

1 reference

1 August 2017

Tadao Akizawa

1 reference

1 August 2017

Paul Audhya

1 reference

1 August 2017

George L Bakris

1 reference

1 August 2017

Melanie Chin

1 reference

1 August 2017

Heidi Christ-Schmidt

1 reference

1 August 2017

Angie Goldsberry

1 reference

1 August 2017

Melissa Krauth

1 reference

1 August 2017

Hiddo J Lambers Heerspink

1 reference

1 August 2017

Colin J Meyer

1 reference

1 August 2017

Nosratola D Vaziri

1 reference

1 August 2017

Danielle Wrolstad

1 reference

1 August 2017

Glenn M Chertow

1 reference

1 August 2017

Christoph Wanner

1 reference

1 August 2017

Dick de Zeeuw

1 reference

1 August 2017

Mark Houser

series ordinal

1 reference

1 August 2017

BEACON Trial Investigators

series ordinal

1 reference

1 August 2017

language of work or name

English

0 references

publication date

9 November 2013

1 reference

The New England Journal of Medicine

1 August 2017

published in

1 reference

1 August 2017

volume

369

1 reference

1 August 2017

1 reference

1 August 2017

page(s)

2492-2503

1 reference

Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Bardoxolone methyl decreases megalin and activates nrf2 in the kidney

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

The kidney in type 2 diabetes therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Bardoxolone methyl and kidney function in CKD with type 2 diabetes

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

The Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic-acid Methyl Ester Has Potent Anti-diabetic Effects in Diet-induced Diabetic Mice and Lepr Mice

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Avosentan for overt diabetic nephropathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Combined angiotensin inhibition for the treatment of diabetic nephropathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy

9 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24206459

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24206459

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1056/NEJMOA1306033

1 reference

1 August 2017

1 reference

1 August 2017

1 reference